Neurobo Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.45
- Today's High:
- $0.47
- Open Price:
- $0.459
- 52W Low:
- $0.361
- 52W High:
- $29.88
- Prev. Close:
- $0.454
- Volume:
- 63261
Company Statistics
- Market Cap.:
- $17.49 million
- Book Value:
- 0.659
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -37.09%
- Return on Equity TTM:
- -65.4%
Company Profile
Neurobo Pharmaceuticals Inc had its IPO on 2016-08-05 under the ticker symbol NRBO.
The company operates in the Healthcare sector and Biotechnology industry. Neurobo Pharmaceuticals Inc has a staff strength of 2 employees.
Stock update
Shares of Neurobo Pharmaceuticals Inc opened at $0.46 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.45 - $0.47, and closed at $0.46.
This is a +2.2% increase from the previous day's closing price.
A total volume of 63,261 shares were traded at the close of the day’s session.
In the last one week, shares of Neurobo Pharmaceuticals Inc have increased by +1.98%.
Neurobo Pharmaceuticals Inc's Key Ratios
Neurobo Pharmaceuticals Inc has a market cap of $17.49 million, indicating a price to book ratio of 1.84 and a price to sales ratio of 0.
In the last 12-months Neurobo Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-11646000. The EBITDA ratio measures Neurobo Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Neurobo Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -37.09% with a return of equity of -65.4%.
In Q2, Neurobo Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Neurobo Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-8.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Neurobo Pharmaceuticals Inc’s profitability.
Neurobo Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.3325. Its price to sales ratio in the trailing 12-months stood at 0.
Neurobo Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $29.18 million
- Total Liabilities
- $3.98 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Neurobo Pharmaceuticals Inc ended 2024 with $29.18 million in total assets and $0 in total liabilities. Its intangible assets were valued at $29.18 million while shareholder equity stood at $25.20 million.
Neurobo Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $3.98 million in other current liabilities, 38000.00 in common stock, $-99133000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $28.69 million and cash and short-term investments were $28.69 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Neurobo Pharmaceuticals Inc’s total current assets stands at $29.17 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $967000.00 and inventory worth $0.
In 2024, Neurobo Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Neurobo Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.46
- 52-Week High
- $29.88
- 52-Week Low
- $0.361
- Analyst Target Price
- $6
Neurobo Pharmaceuticals Inc stock is currently trading at $0.46 per share. It touched a 52-week high of $29.88 and a 52-week low of $29.88. Analysts tracking the stock have a 12-month average target price of $6.
Its 50-day moving average was $0.51 and 200-day moving average was $0.71 The short ratio stood at 0.55 indicating a short percent outstanding of 0%.
Around 5018.2% of the company’s stock are held by insiders while 113.5% are held by institutions.
Frequently Asked Questions About Neurobo Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.